International Association of Scientists
www.iasnetedu.com

Available online at www.jobiost.com
IJBLS 2023; 2(2):253-260

International Journal of BioLife Sciences

Review paper

Emerging Trends in Cancer Biomarkers: From Molecular Signatures to Clinical Applications

Maedeh Ghorbani*

Department of Biology, Tehran University, Tehran, Iran

***Received**: 15 September 2023* ***Revised**: 24 September 2023* ***Accepted**: 2 October 2023*

Abstract

Background and aim: Cancer remains a global health challenge, necessitating the continual evolution of diagnostic and therapeutic strategies. This review paper explores the current landscape of cancer biomarkers, focusing on the transition from molecular signatures to their clinical applications. The aim is to provide a comprehensive overview of recent developments in cancer biomarker research and their potential impact on early detection, prognosis, and personalized treatment approaches.

Methods: We conducted an extensive literature review to identify relevant studies and developments in cancer biomarkers. The selected articles encompassed various types of biomarkers, including genetic, epigenetic, proteomic, and liquid biopsy markers. Our analysis considers the methodologies employed for biomarker discovery, validation, and clinical implementation. We also highlight the emerging technologies and bioinformatics tools that have revolutionized the field.

Results: Our review reveals a multitude of promising cancer biomarkers, many of which have transitioned from the laboratory to clinical settings. Advances in genomics and high-throughput sequencing technologies have enabled the identification of novel genetic mutations associated with cancer. Epigenetic modifications have provided valuable insights into cancer development and progression. Proteomic approaches have unveiled protein biomarkers with diagnostic and prognostic potential. Liquid biopsies, featuring circulating tumor DNA and exosomes, hold promise for real-time monitoring and treatment response assessment.

Conclusion: The emergence of cancer biomarkers in clinical oncology represents a significant paradigm shift. These molecular signatures offer improved diagnostic accuracy, early detection capabilities, and personalized treatment options. However, challenges remain, including standardization of methodologies, validation across diverse patient populations, and integration into routine clinical practice.

Keywords: *Cancer Biomarkers, Molecular signatures, Clinical applications, Personalized medicine*

***Corresponding author:** Maedeh Ghorbani, Department of Biology, Tehran University, Tehran, Iran.

E-mail address: maede.gh1371@gmail.com

Introduction

The area of cancer research has undergone a significant metamorphosis in recent times, witnessing a transformative surge in the identification and utilization of biomarkers. Moving beyond traditional markers, the focus has shifted to intricate molecular signatures that hold promise for enhancing diagnostic accuracy, prognostic insight, and targeted therapeutic interventions [1], [2], [3], [4]. This review explores the cutting-edge trends in cancer biomarkers, tracing the path from molecular revelations to their application in clinical scenarios. By examining the latest developments, addressing challenges, and highlighting potential breakthroughs, this paper aims to offer a comprehensive insight into the pivotal role of biomarkers in shaping the future landscape of cancer diagnosis, prognosis, and personalized treatment strategies.

Cancer biomarkers

- *Genetic cancer biomarkers*

Genetic cancer biomarkers constitute specific and discernible genetic alterations or variations inherent in the DNA of cancer cells, wielding a pivotal influence on cancer initiation, progression, and behavior. The identification and comprehension of these genetic biomarkers represent a groundbreaking stride in our grasp of cancer biology, furnishing indispensable insights into the intricate molecular mechanisms steering the disease's course. Functioning as clinical linchpins, biomarkers not only empower early diagnosis, prognosis, and ongoing disease monitoring but also stand as decisive tools in shaping clinical decisions. Encompassing alterations in genetic material structure, expression, or sequence, these genetic markers serve as instrumental tools for diagnosing and affirming genetic predisposition to cancer, while simultaneously facilitating the vigilant monitoring of disease trajectory. The deployment and exploitation of DNA-based molecular markers not only streamline but also intensify investigations into genetic variations, differentiating between healthy and afflicted individuals with greater precision [5], [6].

There are various types of genetic cancer biomarkers, each offering unique information about the characteristics of cancer cells. Some common categories include:

- *Mutation Biomarkers*

These involve changes in the DNA sequence of specific genes. Mutations can either be inherited (germline mutations) or acquired during an individual's lifetime (somatic mutations). Mutated genes often encode proteins involved in cell cycle regulation, DNA repair, or signaling pathways, and their alterations can contribute to uncontrolled cell growth. In the context of cancer, mutations play a pivotal role in the initiation, development, and progression of the disease [7], [8], [9]. Key aspects of mutation biomarkers in cancer include:

1. Driver Mutations:

Driver mutations serve as informative biomarkers, particularly when targeted treatments have been designed to address these specific genetic alterations. The presence of an abnormal protein resulting from a driver mutation in cancer cells indicates the potential efficacy of treatments tailored to target that specific mutation. However, it's crucial to note that not all cancers exhibit a distinct driver mutation. These mutations play a direct role in fostering the development and advancement of cancer and are often found in genes that regulate fundamental cellular processes like cell cycle control, DNA repair, and apoptosis. Such mutations provide affected cells with a growth advantage, resulting in uncontrolled proliferation and tumor formation. While cancer cells accumulate numerous genetic alterations over time, only a select few, termed driver mutations, actively propel cancer progression. Importantly, these driver mutations may differ across cancer types and patients. They can remain dormant for extended periods, only becoming drivers at specific stages of cancer development, or may act as drivers in conjunction with other mutations.

Understanding the dynamic nature of driver mutations is critical in deciphering the intricate landscape of cancer genetics and tailoring effective therapeutic interventions [10], [11], [12].

2. Passenger Mutations:

In contrast to driver mutations, passenger mutations lack a direct contribution to the cancer phenotype; rather, they are incidental alterations arising from genomic instability within cancer cells. Although these mutations do not actively promote cancer growth, their identification holds significance in unraveling the genetic terrain of a tumor and tracing its evolutionary history. The prevalence of genomic instability and elevated mutation rates in cancer results in the acquisition of numerous mutations and chromosomal alterations during somatic evolution. Referred to as passengers, the majority of these alterations do not confer cancer phenotypes. Evolutionary simulations and studies in cancer genomics suggest that while mildly deleterious passengers accumulate, their collective presence might paradoxically exert a decelerating influence on cancer progression. Understanding the interplay between driver and passenger mutations provides crucial insights into the intricate dynamics governing cancer evolution [13], [14].

3. Somatic Mutations:

These mutations specifically manifest in the DNA of somatic cells, which are non-germline cells and thus not inherited. Somatic mutations stand as the primary instigators of cancer development, fostering the accrual of genetic alterations that play pivotal roles in initiating and advancing tumors. Present in the genomes of all dividing cells, whether normal or neoplastic, somatic mutations may arise from misincorporations during DNA replication or due to exposure to external or internal mutagens. Particularly, somatic mutations occurring in driver genes have the potential to culminate in cancer development. A comprehensive understanding of the mechanisms governing the accumulation of somatic mutations in cancer genomes, as well as the intrinsic and extrinsic factors influencing their generation, is imperative for the formulation of innovative therapeutic strategies [15], [16].

4. Germline Mutations:

Germline mutations, alternatively known as hereditary mutations, are transmitted from parents to their offspring. Inherited germline mutations significantly influence the risk and susceptibility of an individual to cancer. Understanding these hereditary mutations is pivotal in devising preventive measures aimed at diminishing the chances of cancer development. Unlike somatic mutations, germline mutations reside in the DNA of reproductive cells and have the potential to be passed on from one generation to the next. Individuals harboring germline mutations in specific cancer-related genes may exhibit an elevated predisposition to developing particular types of cancer. Unraveling the genetic landscape shaped by germline mutations holds great promise for advancing targeted strategies in cancer prevention [17], [18].

- *Copy Number Variation Biomarkers*

Copy Number Variants (CNVs) have emerged as compelling biomarkers for cancer diagnosis, presenting a potential superiority over mRNA biomarkers due to their heightened stability and robustness compared to gene expression. These CNV biomarkers in cancer signify alterations in the copy number of specific genomic regions, playing a pivotal role in tumorigenesis. Encompassing amplifications of oncogenes, leading to their overexpression and fostering cancer-related characteristics, as well as deletions of tumor suppressor genes compromising their growth-regulating function, CNVs serve as diagnostic and prognostic markers. They contribute to identifying cancer types and predicting disease outcomes, simultaneously offering promising avenues for targeted therapies, especially in precision medicine. The monitoring of CNVs during treatment provides valuable insights into treatment response dynamics and the emergence of drug

resistance. The detection of CNVs employs sophisticated molecular techniques such as array-based comparative genomic hybridization and next-generation sequencing, significantly advancing our comprehension of cancer genetics. This, in turn, enhances diagnostic accuracy and facilitates the development of personalized treatment strategies, marking a transformative stride in cancer research and patient care [19], [20].

- *Translocation Biomarkers*

Translocation biomarkers in cancer refer to abnormal rearrangements of genetic material between different chromosomes. Translocations play a significant role in the development and progression of cancer by creating novel fusion genes or altering the regulation of existing genes. One well-known example is the BCR-ABL1 fusion gene resulting from the Philadelphia chromosome translocation, which is characteristic of chronic myeloid leukemia (CML). These fusion genes often encode proteins with aberrant functions, promoting uncontrolled cell growth and survival. Detection of translocation biomarkers is crucial for cancer diagnosis, classification, and treatment planning. Techniques such as fluorescence in situ hybridization (FISH) and molecular methods like polymerase chain reaction (PCR) are commonly used to identify translocations. Understanding these biomarkers not only aids in the accurate diagnosis of specific cancer types but also provides valuable information for targeted therapies, as drugs can be designed to inhibit the products of these fusion genes, offering more precise and effective treatment strategies [21], [22].

- *Epigenetic Biomarkers*

Epigenetic modifications and regulators emerge as pivotal molecular components influencing crucial physiological and pathological aspects, thereby shaping the natural history of human diseases. These epigenetic modulators offer promise as disease biomarkers, showcasing distinct advantages and providing insights into gene function, elucidating variations among patient endophenotypes [23]. In the context of cancer, epigenetic biomarkers signify alterations in chemical modifications governing gene expression, independent of changes in the underlying DNA sequence. DNA methylation, histone modifications, and non-coding RNA expression constitute key epigenetic modifications playing a vital role in orchestrating gene activity. Dysregulated epigenetic changes in cancer can activate oncogenes or silence tumor suppressor genes, contributing to tumorigenesis and disease progression. Notably, DNA hypermethylation, particularly in promoter regions of tumor suppressor genes, and global hypomethylation leading to genomic instability are prevalent epigenetic alterations in cancer. Epigenetic biomarkers have significantly advanced our comprehension of disease origins and progression. Moreover, a growing body of evidence suggests their potential for personalized medicine. The detection of these epigenetic biomarkers holds crucial importance for cancer diagnosis, prognosis, and predicting treatment responses. Cutting-edge technologies such as DNA methylation arrays and next-generation sequencing are employed to profile epigenetic changes in cancer cells. A profound understanding of epigenetic biomarkers not only enriches our knowledge of cancer biology but also paves the way for the development of epigenetic therapies. These therapies, including drugs targeting specific epigenetic modifications, hold promise for more precise and personalized cancer treatments [24], [25]. The integration of epigenetics into cancer research not only augments our understanding of disease mechanisms but also propels us towards more effective and tailored therapeutic interventions.

Methods

An extensive literature review was conducted to identify relevant studies and developments in

cancer biomarkers. Various types of biomarkers, including genetic, epigenetic, proteomic, and liquid biopsy markers, were encompassed by the selected articles. The methodologies employed for biomarker discovery, validation, and clinical implementation are considered in our analysis. Additionally, the emerging technologies and bioinformatics tools that have revolutionized the field are highlighted.

Results

Our mini review underscores the wealth of promising cancer biomarkers, a considerable number of which have successfully made the transition from laboratory discoveries to practical applications in clinical settings. The advent of cutting-edge genomics and high-throughput sequencing technologies has played a pivotal role in unveiling novel genetic mutations intricately linked to various types of cancer. Equally significant has been the exploration of epigenetic modifications, offering profound insights into the intricate mechanisms governing cancer development and progression. Proteomic methodologies have further contributed to this landscape by identifying protein biomarkers that exhibit substantial diagnostic and prognostic potential in the realm of cancer research. Emphasizing the frontier of liquid biopsies, encompassing circulating tumor DNA and exosomes, holds exceptional promise for revolutionizing real-time monitoring and the assessment of treatment responses, marking a paradigm shift in cancer diagnostics and personalized therapeutics. These interdisciplinary advancements collectively underscore the strides made in the identification and application of diverse cancer biomarkers, fostering a more nuanced understanding of cancer biology and paving the way for innovative diagnostic and treatment strategies.

Discussion

This concise review illuminates the dynamic realm of cancer research, wherein advancements in molecular profiling have unveiled a plethora of promising biomarkers, holding transformative implications for clinical practice. Despite their critical role in rational therapeutics development, confusion lingers around fundamental definitions and concepts associated with biomarkers, particularly in the context of chronic diseases [26]. The integration of cutting-edge technologies, spanning genomics, epigenetics, and proteomics, has been instrumental in unraveling the intricate molecular signatures characterizing various cancer types [27], [28], [29]. These molecular signatures not only facilitate early detection but also provide crucial insights into the underlying mechanisms of tumorigenesis and progression. The successful transition of numerous biomarkers from laboratory exploration to clinical applications underscores the potential for personalized and targeted cancer diagnostics and therapeutics.

Exploration of genetic mutations, facilitated by high-throughput sequencing, has unearthed novel markers holding immense promise for early cancer detection and risk assessment. Concurrently, the investigation of epigenetic modifications has shed light on the pivotal role of non-genetic factors in cancer development, paving the way for identifying epigenetic biomarkers that complement genetic signatures [30]. The burgeoning field of proteomics has made substantial contributions by uncovering protein biomarkers that not only serve as diagnostic tools but also offer prognostic insights, guiding treatment decisions [31].

A noteworthy frontier in cancer biomarker research lies in liquid biopsies, encompassing circulating tumor DNA and exosomes [32]. These non-invasive approaches possess the potential to revolutionize cancer monitoring, furnishing real-time information on disease progression and treatment response. The integration of liquid biopsies into clinical practice could herald an era of

precision medicine, tailoring therapies based on dynamic changes in the tumor landscape [33]. Despite promising strides in cancer biomarker discovery, several challenges persist, including the imperative need for standardized validation processes and the establishment of robust clinical utility. The inherent heterogeneity of cancer [34] poses a complex puzzle, necessitating a nuanced understanding of the interplay between various biomarkers and their implications for diverse patient populations.

Conclusion

The advent of cancer biomarkers in clinical oncology signifies a transformative paradigm shift, promising enhanced diagnostic accuracy, early detection capabilities, and tailored treatment strategies. These molecular signatures hold the potential to revolutionize patient care by providing clinicians with precise and timely information about the molecular intricacies of tumors. Despite the remarkable progress, several challenges persist on the road to widespread clinical adoption. Standardizing methodologies across various research and clinical settings is essential to ensure the reliability and reproducibility of biomarker data. Additionally, the validation of these biomarkers in diverse patient populations is critical for their robustness and applicability across different demographic and genetic contexts. The successful integration of these biomarkers into routine clinical practice requires a concerted effort involving multidisciplinary collaboration, clear regulatory frameworks, and the development of user-friendly technologies. As we navigate these challenges, the continued exploration and refinement of cancer biomarkers promise to reshape the landscape of oncology, offering more precise and personalized approaches to cancer diagnosis and treatment.

Acknowledgement

The author would like to express gratitude to the GREEN staff for their invaluable help and unwavering support.

Conflict of interest

The author declares no conflict of interest.

References

[1]. Ganesh K, Massague J. Targeting metastatic cancer. Nature medicine. 2021;27(1):34-44.
[2]. Esfahani K, Roudaia L, Buhlaiga NA, Del Rincon SV, Papneja N, Miller WH. A review of cancer immunotherapy: from the past, to the present, to the future. Current Oncology. 2020;27(s2):87-97.
[3]. Khan H, Shah MR, Barek J, Malik MI. Cancer biomarkers and their biosensors: A comprehensive review. TrAC Trends in Analytical Chemistry. 2023;158:116813.
[4]. Haj Hossein Javaheri F, Tabaku M. Investigating the Impact of a Bioactive Nitro Derivative of Pyrimidine on Human Breast Cancer (MCF-7) Cells through Flow Cytometry and Western Blot Analysis. International Journal of BioLife Sciences (IJBLS). 2023;2(1):117-22.
[5]. Khan H, Shah MR, Barek J, Malik MI. Cancer biomarkers and their biosensors: A comprehensive review. TrAC Trends in Analytical Chemistry. 2023;158:116813.
[6]. Wadowska K, Bil-Lula I, Trembecki Ł, Śliwińska-Mossoń M. Genetic markers in lung cancer diagnosis: A review. International journal of molecular sciences. 2020;21(13):4569.
[7]. Klempner SJ, Fabrizio D, Bane S, Reinhart M, Peoples T, Ali SM, Sokol ES, Frampton G, Schrock AB, Anhorn R, Reddy P. Tumor mutational burden as a predictive biomarker for response

to immune checkpoint inhibitors: a review of current evidence. The oncologist. 2020;25(1):e147-59.
[8]. Harris KL, Myers MB, McKim KL, Elespuru RK, Parsons BL. Rationale and roadmap for developing panels of hotspot cancer driver gene mutations as biomarkers of cancer risk. Environmental and molecular mutagenesis. 2020;61(1):152-75.
[9]. Fang Y, Zheng Y, Chen J, Ying J, Lou H, Chen E, Li D, Rao C, Du F, Shou J, Pan H. Genetic mutation as biomarker for advanced cancer patients receiving apatinib: An analysis based on whole exome sequencing. Journal of Clinical Oncology. 2018;36(15):e24219.
[10]. Ostroverkhova D, Przytycka TM, Panchenko AR. Cancer driver mutations: predictions and reality. Trends Mol Med. 2023;29(7):554-566.
[11]. Elliott K, Larsson E. Non-coding driver mutations in human cancer. Nature Reviews Cancer. 2021;21(8):500-9.
[12]. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Ng PK. Comprehensive characterization of cancer driver genes and mutations. Cell. 2018;173(2):371-85.
[13]. McFarland CD, Yaglom JA, Wojtkowiak JW, Scott JG, Morse DL, Sherman MY, Mirny LA. The damaging effect of passenger mutations on cancer progression. Cancer research. 2017;77(18):4763-72.
[14]. Hess JM, Bernards A, Kim J, Miller M, Taylor-Weiner A, Haradhvala NJ, Lawrence MS, Getz G. Passenger hotspot mutations in cancer. Cancer Cell. 2019;36(3):288-301.
[15]. Li Y, Roberts ND, Wala JA, Shapira O, Schumacher SE, Kumar K, Khurana E, Waszak S, Korbel JO, Haber JE, Imielinski M. Patterns of somatic structural variation in human cancer genomes. Nature. 2020;578(7793):112-21.
[16]. Akdemir KC, Le VT, Kim JM, Killcoyne S, King DA, Lin YP, Tian Y, Inoue A, Amin SB, Robinson FS, Nimmakayalu M. Somatic mutation distributions in cancer genomes vary with three-dimensional chromatin structure. Nature genetics. 2020;52(11):1178-88.
[17]. Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, Hedges D, Ma X, Zhou X, Yergeau DA, Wilkinson MR, Vadodaria B, Chen X, McGee RB, Hines-Dowell S, Nuccio R, Quinn E, Shurtleff SA, Rusch M, Patel A, Becksfort JB, Wang S, Weaver MS, Ding L, Mardis ER, Wilson RK, Gajjar A, Ellison DW, Pappo AS, Pui CH, Nichols KE, Downing JR. Germline Mutations in Predisposition Genes in Pediatric Cancer. N Engl J Med. 2015;373(24):2336-2346.
[18]. Hu C, Hart SN, Polley EC, Gnanaolivu R, Shimelis H, Lee KY, Lilyquist J, Na J, Moore R, Antwi SO, Bamlet WR, Chaffee KG, DiCarlo J, Wu Z, Samara R, Kasi PM, McWilliams RR, Petersen GM, Couch FJ. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. JAMA. 2018;319(23):2401-2409.
[19]. Pan X, Hu X, Zhang YH, Chen L, Zhu L, Wan S, Huang T, Cai YD. Identification of the copy number variant biomarkers for breast cancer subtypes. Molecular Genetics and Genomics. 2019;294:95-110.
[20]. Ren J, Kong P, Wang Y, Guo D, Zhang L. Copy number variations in esophageal squamous cell carcinoma: Emerging cancer drivers and biomarkers. Oncology Reports. 2024;51(1):1-2.
[21]. Sampaio MM, Santos ML, Marques HS, de Souza Gonçalves VL, Araújo GR, Lopes LW, Apolonio JS, Silva CS, de Sá Santos LK, Cuzzuol BR, Guimarães QE. Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review. World journal of clinical oncology. 2021;12(2):69.
[22]. Ratan ZA, Zaman SB, Mehta V, Haidere MF, Runa NJ, Akter N, RATAN ZA. Application of fluorescence in situ hybridization (FISH) technique for the detection of genetic aberration in

medical science. Cureus. 2017;9(6).
[23]. García-Giménez JL, Seco-Cervera M, Tollefsbol TO, Romá-Mateo C, Peiró-Chova L, Lapunzina P, Pallardó FV. Epigenetic biomarkers: Current strategies and future challenges for their use in the clinical laboratory. Crit Rev Clin Lab Sci. 2017;54(7-8):529-550.
[24]. Grady WM. Epigenetic alterations in the gastrointestinal tract: current and emerging use for biomarkers of cancer. Advances in cancer research. 2021;151:425-68.
[25]. Verma M, Kumar V. Epigenetic biomarkers in colorectal cancer. Molecular diagnosis & therapy. 2017;21:153-65.
[26]. Califf RM. Biomarker definitions and their applications. Experimental Biology and Medicine. 2018;243(3):213-21.
[27]. Su M, Zhang Z, Zhou L, Han C, Huang C, Nice EC. Proteomics, personalized medicine and cancer. Cancers. 2021;13(11):2512.
[28]. Karczewski KJ, Snyder MP. Integrative omics for health and disease. Nature Reviews Genetics. 2018;19(5):299-310.
[29]. Zhu Z, Jiang L, Ding X. Advancing breast cancer heterogeneity analysis: Insights from genomics, transcriptomics and proteomics at bulk and single-cell levels. Cancers. 2023;15(16):4164.
[30]. Shlyakhtina Y, Moran KL, Portal MM. Genetic and non-genetic mechanisms underlying cancer evolution. Cancers. 2021;13(6):1380.
[31]. Kwon YW, Jo HS, Bae S, Seo Y, Song P, Song M, Yoon JH. Application of proteomics in cancer: recent trends and approaches for biomarkers discovery. Frontiers in Medicine. 2021;8:747333.
[32]. Zhang W, Xia W, Lv Z, Ni C, Xin Y, Yang L. Liquid biopsy for cancer: circulating tumor cells, circulating free DNA or exosomes?. Cellular Physiology and Biochemistry. 2017;41(2):755-68.
[33]. Yu W, Hurley J, Roberts D, Chakrabortty SK, Enderle D, Noerholm M, Breakefield XO, Skog JK. Exosome-based liquid biopsies in cancer: opportunities and challenges. Annals of Oncology. 2021;32(4):466-77.
[34]. Turajlic S, Sottoriva A, Graham T, Swanton C. Resolving genetic heterogeneity in cancer. Nature Reviews Genetics. 2019;20(7):404-16.